Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
MANNING JOSEPH JSenior Vice President
|
SaleCommon shares without par value | 387 | $44.96 | $17,400.95 |
DisclosureSEC source: 0001179110-17-003682 · edgar.xml · nonDerivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,381 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
MANNING JOSEPH JSenior Vice President
|
Tax withholdingCommon shares without par value | 1,463 | $45.46 | $66,507.98 |
DisclosureSEC source: 0001179110-17-003682 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,768 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
MANNING JOSEPH JSenior Vice President
|
GrantCommon shares without par value | 5,085 | $45.46 | $231,164.10 |
DisclosureSEC source: 0001179110-17-003682 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,231 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:19 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Tax withholdingCommon shares without par value | 4,227 | $45.46 | $192,159.42 |
DisclosureSEC source: 0001179110-17-003683 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,153 Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 22:28 UTC |
Funck, Jr. Robert E.Vice President, Controller
|
Exercise / conversionOption (right to buy) · Derivative | 25,500 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-17-003180 · edgar.xml · derivative · entry 6 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 25,500 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 22:28 UTC |
Funck, Jr. Robert E.Vice President, Controller
|
SaleCommon shares without par value | 25,500 | $45.50 | $1,160,250.00 |
DisclosureSEC source: 0001179110-17-003180 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,079 Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 22:28 UTC |
Funck, Jr. Robert E.Vice President, Controller
|
Exercise / conversionCommon shares without par value | 25,500 | $26.70 | $680,781.15 |
DisclosureSEC source: 0001179110-17-003180 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 1,873 | $0.00 Strike: $26.20 | $0.00 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · derivative · entry 16 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,873 shares Expires 2018-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 11,030 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · derivative · entry 15 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 11,030 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
SaleCommon shares without par value | 167 | $45.05 | $7,522.52 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 13 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,864 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
SaleCommon shares without par value | 100 | $45.04 | $4,504.10 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 12 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,031 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
SaleCommon shares without par value | 400 | $45.04 | $18,016.00 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 11 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,131 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
SaleCommon shares without par value | 1,500 | $45.04 | $67,552.50 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 10 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,531 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
SaleCommon shares without par value | 100 | $45.03 | $4,503.10 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 9 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,031 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
SaleCommon shares without par value | 700 | $45.03 | $31,521.00 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 8 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,131 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
SaleCommon shares without par value | 9,936 | $45.02 | $447,318.72 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 7 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,831 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
Exercise / conversionCommon shares without par value | 1,873 | $26.20 | $49,068.10 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 6 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
Exercise / conversionCommon shares without par value | 11,030 | $26.70 | $294,471.22 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 5 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:34 UTC |
NATH DEEPAK S.Senior Vice President
|
SaleCommon shares without par value | 319 | $44.98 | $14,348.94 |
DisclosureSEC source: 0001179110-17-002931 · edgar.xml · nonDerivative · entry 3 NATH DEEPAK S. · CIK 0001636628 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,333 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:34 UTC |
NATH DEEPAK S.Senior Vice President
|
Tax withholdingCommon shares without par value | 819 | $44.69 | $36,601.11 |
DisclosureSEC source: 0001179110-17-002931 · edgar.xml · nonDerivative · entry 2 NATH DEEPAK S. · CIK 0001636628 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,652 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC |
Watkin JaredSenior Vice President
|
SaleCommon shares without par value | 55 | $44.99 | $2,474.29 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 7 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,977 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC |
Watkin JaredSenior Vice President
|
SaleCommon shares without par value | 100 | $44.99 | $4,498.50 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 6 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,032 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC |
Watkin JaredSenior Vice President
|
SaleCommon shares without par value | 100 | $44.98 | $4,498.10 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 5 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,132 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC |
Watkin JaredSenior Vice President
|
SaleCommon shares without par value | 300 | $44.98 | $13,494.00 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 4 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,232 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC |
Watkin JaredSenior Vice President
|
Tax withholdingCommon shares without par value | 683 | $44.69 | $30,523.27 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,532 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC |
CAPEK JOHN MExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 93,400 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-17-002952 · edgar.xml · derivative · entry 5 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 93,400 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC |
CAPEK JOHN MExecutive Vice President
|
SaleCommon shares without par value | 93,400 | $45.00 | $4,203,000.00 |
DisclosureSEC source: 0001179110-17-002952 · edgar.xml · nonDerivative · entry 3 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,797 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC |
CAPEK JOHN MExecutive Vice President
|
Exercise / conversionCommon shares without par value | 93,400 | $26.70 | $2,493,527.82 |
DisclosureSEC source: 0001179110-17-002952 · edgar.xml · nonDerivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
SaleCommon shares without par value | 100 | $45.00 | $4,499.50 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 4 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,864 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
SaleCommon shares without par value | 219 | $44.91 | $9,835.29 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 3 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,964 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:59 UTC |
BIRD ROGERSenior Vice President
|
Tax withholdingCommon shares without par value | 727 | $44.69 | $32,489.63 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,183 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 23:18 UTC |
MANNING JOSEPH JSenior Vice President
|
SaleCommon shares without par value | 146 | $44.98 | $6,567.23 |
DisclosureSEC source: 0001179110-17-002974 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,146 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 23:18 UTC |
MANNING JOSEPH JSenior Vice President
|
Tax withholdingCommon shares without par value | 287 | $44.69 | $12,826.03 |
DisclosureSEC source: 0001179110-17-002974 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,292 Read SEC document |
| February 20, 2017 Filed Feb 22, 2017 22:57 UTC |
Watkin JaredSenior Vice President
|
Tax withholdingCommon shares without par value | 740 | $44.69 | $33,070.60 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,215 Read SEC document |
| February 20, 2017 Filed Feb 22, 2017 23:08 UTC |
LANE ANDREW HSenior Vice President
|
Tax withholdingCommon shares without par value | 605 | $44.69 | $27,037.45 |
DisclosureSEC source: 0001179110-17-002964 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,176 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:19 UTC |
Fain Eric SSenior Vice President
|
GrantOption (right to buy) · Derivative | 159,657 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002920 · edgar.xml · derivative · entry 2 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,657 Underlying: Common shares · 159,657 shares Expires 2027-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 53,219 on 02/17/2018, 53,219 on 02/17/2019, and 53,219 on 02/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:19 UTC |
Fain Eric SSenior Vice President
|
GrantCommon shares without par value | 23,085 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002920 · edgar.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,052 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. F2 · balance_after: Due to administrative error, the previously reported beneficial ownership for this reporting person was overstated by 1 share. This Form 4 reflects the corrected total beneficial ownership for this reporting person. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:20 UTC |
Contreras JaimeSenior Vice President
|
GrantOption (right to buy) · Derivative | 138,049 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002921 · edgar.xml · derivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,049 Underlying: Common shares · 138,049 shares Expires 2027-02-16 F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 46,017 on 02/17/2018, 46,016 on 02/17/2019, and 46,016 on 02/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:20 UTC |
Contreras JaimeSenior Vice President
|
GrantCommon shares without par value | 19,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002921 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,628 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:21 UTC |
Fussell Stephen RExecutive Vice President
|
GrantOption (right to buy) · Derivative | 182,242 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002922 · edgar.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,242 Underlying: Common shares · 182,242 shares Expires 2027-02-16 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 60,748 on 02/17/2018, 60,747 on 02/17/2019, and 60,747 on 02/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:21 UTC |
Fussell Stephen RExecutive Vice President
|
GrantCommon shares without par value | 26,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002922 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,518 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:21 UTC |
Ford Robert BExecutive Vice President
|
GrantOption (right to buy) · Derivative | 151,869 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002923 · edgar.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,869 Underlying: Common shares · 151,869 shares Expires 2027-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 50,623 on 02/17/2018, 50,623 on 02/17/2019, and 50,623 on 02/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:21 UTC |
Ford Robert BExecutive Vice President
|
GrantCommon shares without par value | 21,959 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002923 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,491 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:34 UTC |
NATH DEEPAK S.Senior Vice President
|
GrantOption (right to buy) · Derivative | 76,693 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002931 · edgar.xml · derivative · entry 4 NATH DEEPAK S. · CIK 0001636628 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,693 Underlying: Common shares · 76,693 shares Expires 2027-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,565 on 2/17/2018, 25,564 on 2/17/2019, and 25,564 on 2/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:34 UTC |
NATH DEEPAK S.Senior Vice President
|
GrantCommon shares without par value | 11,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002931 · edgar.xml · nonDerivative · entry 1 NATH DEEPAK S. · CIK 0001636628 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,471 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:34 UTC |
Mason Heather LExecutive Vice President
|
GrantOption (right to buy) · Derivative | 38,940 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002933 · edgar.xml · derivative · entry 3 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,940 Underlying: Common shares · 38,940 shares Expires 2027-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,980 on 02/17/2018, 12,980 on 02/17/2019, and 12,980 on 02/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:34 UTC |
Mason Heather LExecutive Vice President
|
GrantCommon shares without par value | 5,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002933 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,119 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:57 UTC |
Watkin JaredSenior Vice President
|
GrantOption (right to buy) · Derivative | 51,129 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · derivative · entry 9 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,129 Underlying: Common shares · 51,129 shares Expires 2027-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,043 on 02/17/2018, 17,043 on 02/17/2019, and 17,043 on 02/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:57 UTC |
Watkin JaredSenior Vice President
|
GrantCommon shares without par value | 7,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,955 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:57 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantOption (right to buy) · Derivative | 98,714 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002952 · edgar.xml · derivative · entry 4 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,714 Underlying: Common shares · 98,714 shares Expires 2027-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,905 on 2/17/2018, 32,904 on 2/17/2019, and 32,905 on 2/17/2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.